Leitner, T., Shumilov, E., Schwitlick, C., Koch, R., Hamm, F., Högner, M., . . . Khandanpour, C. Comparison of 6 cycles of isatuximab with lenalidomide, bortezomib and dexamethasone (I-VRd) versus 3 cycles of I-VRd followed by one cycle of high-dose melphalan in newly diagnosed low-risk multiple myeloma. Protocol for a multicenter, prospective, randomized, phase II clinical trial (ELIAS-Trial). Frontiers Media S.A.
Chicago Style (17th ed.) CitationLeitner, Theo, et al. Comparison of 6 Cycles of Isatuximab with Lenalidomide, Bortezomib and Dexamethasone (I-VRd) Versus 3 Cycles of I-VRd Followed by One Cycle of High-dose Melphalan in Newly Diagnosed Low-risk Multiple Myeloma. Protocol for a Multicenter, Prospective, Randomized, Phase II Clinical Trial (ELIAS-Trial). Frontiers Media S.A.
MLA (9th ed.) CitationLeitner, Theo, et al. Comparison of 6 Cycles of Isatuximab with Lenalidomide, Bortezomib and Dexamethasone (I-VRd) Versus 3 Cycles of I-VRd Followed by One Cycle of High-dose Melphalan in Newly Diagnosed Low-risk Multiple Myeloma. Protocol for a Multicenter, Prospective, Randomized, Phase II Clinical Trial (ELIAS-Trial). Frontiers Media S.A.